Surmodics reports Q1 EPS (4c), consensus (12c)

Reports Q1 revenue $29.92M, consensus $33.37M. “We were pleased with the efforts of our team during first quarter of fiscal 2025, which enabled Surmodics (SRDX) to deliver strong growth in revenue from both our medical device performance coatings royalties and sales of our Pounce thrombectomy platforms,” said Gary Maharaj, President and CEO of Surmodics, Inc. “This performance helped to offset the year-over-year decrease in SurVeil DCB revenue, which was expected given the initial stocking shipments made in the prior year period, as well as the impact of order timing in our In Vitro Diagnostics business.”